455 related articles for article (PubMed ID: 11790216)
21. Effects of troglitazone in patients with type 2 diabetes mellitus not adequately controlled by sulfonylureas.
Bunnag P; Puavilai G; Chanprasertyotin S; Chandraprasert S; Suwanwalaikorn S; Suthijumroon A; Benjasuratwong Y; Boonyavarakul A; Nitiyanant W; Sriussadaporn S; Deerochanawong C;
Diabetes Res Clin Pract; 2001 Feb; 51(2):151-3. PubMed ID: 11253769
[No Abstract] [Full Text] [Related]
22. Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.
Iwamoto Y; Kosaka K; Kuzuya T; Akanuma Y; Shigeta Y; Kaneko T
Diabet Med; 1996 Apr; 13(4):365-70. PubMed ID: 9162613
[TBL] [Abstract][Full Text] [Related]
23. Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group.
Horton ES; Whitehouse F; Ghazzi MN; Venable TC; Whitcomb RW
Diabetes Care; 1998 Sep; 21(9):1462-9. PubMed ID: 9727892
[TBL] [Abstract][Full Text] [Related]
24. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
Garber AJ
Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
[No Abstract] [Full Text] [Related]
25. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
26. Targeted glycemic control in type 2 diabetes.
Skyler JS
J Fla Med Assoc; 1998 Aug; 85(2):7-15. PubMed ID: 9782713
[No Abstract] [Full Text] [Related]
27. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen.
Rendell MS; Glazer NB; Ye Z
J Diabetes Complications; 2003; 17(4):211-7. PubMed ID: 12810245
[TBL] [Abstract][Full Text] [Related]
29. Oral combination therapy for type 2 diabetes.
Charpentier G
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989
[TBL] [Abstract][Full Text] [Related]
30. Troglitazone or metformin in combination with sulfonylureas for patients with type 2 diabetes?
Kirk JK; Pearce KA; Michielutte R; Summerson JH
J Fam Pract; 1999 Nov; 48(11):879-82. PubMed ID: 10907625
[TBL] [Abstract][Full Text] [Related]
31. Utilization of oral hypoglycemic agents in a drug-insured U.S. population.
Boccuzzi SJ; Wogen J; Fox J; Sung JC; Shah AB; Kim J
Diabetes Care; 2001 Aug; 24(8):1411-5. PubMed ID: 11473078
[TBL] [Abstract][Full Text] [Related]
32. Type 2 diabetes management: a comprehensive clinical review of oral medications.
Quillen DM; Kuritzky L
Compr Ther; 2002; 28(1):50-61. PubMed ID: 11894443
[TBL] [Abstract][Full Text] [Related]
33. Switching insulin-sensitizing agents in patients with type 2 diabetes who require insulin.
Blonde L; Sandberg MI; Guthrie RD
Diabetes Care; 1999 Jun; 22(6):1004-6. PubMed ID: 10372262
[No Abstract] [Full Text] [Related]
34. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
35. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic management of diabetes mellitus.
Mozersky RP
J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
[TBL] [Abstract][Full Text] [Related]
37. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
39. Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Derosa G; Cicero AF; Gaddi AV; Ciccarelli L; Piccinni MN; Salvadeo S; Pricolo F; Fogari E; Ghelfi M; Ferrari I; Fogari R
Clin Ther; 2005 Sep; 27(9):1383-91. PubMed ID: 16291411
[TBL] [Abstract][Full Text] [Related]
40. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.
Maggs DG; Buchanan TA; Burant CF; Cline G; Gumbiner B; Hsueh WA; Inzucchi S; Kelley D; Nolan J; Olefsky JM; Polonsky KS; Silver D; Valiquett TR; Shulman GI
Ann Intern Med; 1998 Feb; 128(3):176-85. PubMed ID: 9454525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]